JP2023524092A5 - - Google Patents
Info
- Publication number
- JP2023524092A5 JP2023524092A5 JP2022566470A JP2022566470A JP2023524092A5 JP 2023524092 A5 JP2023524092 A5 JP 2023524092A5 JP 2022566470 A JP2022566470 A JP 2022566470A JP 2022566470 A JP2022566470 A JP 2022566470A JP 2023524092 A5 JP2023524092 A5 JP 2023524092A5
- Authority
- JP
- Japan
- Prior art keywords
- dectin
- binder
- antibody
- seq
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063018952P | 2020-05-01 | 2020-05-01 | |
| US63/018,952 | 2020-05-01 | ||
| PCT/US2021/030466 WO2021222894A1 (en) | 2020-05-01 | 2021-05-03 | Anti-dectin-2 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023524092A JP2023524092A (ja) | 2023-06-08 |
| JP2023524092A5 true JP2023524092A5 (https=) | 2024-05-16 |
Family
ID=76076494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022566470A Pending JP2023524092A (ja) | 2020-05-01 | 2021-05-03 | 抗デクチン－２抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11753474B2 (https=) |
| EP (1) | EP4142881A1 (https=) |
| JP (1) | JP2023524092A (https=) |
| KR (1) | KR20230005907A (https=) |
| CN (1) | CN115461122A (https=) |
| AU (1) | AU2021262828A1 (https=) |
| BR (1) | BR112022020639A2 (https=) |
| CA (1) | CA3175576A1 (https=) |
| CL (1) | CL2022003012A1 (https=) |
| CR (1) | CR20220582A (https=) |
| IL (1) | IL297782A (https=) |
| MX (1) | MX2022013616A (https=) |
| WO (1) | WO2021222894A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3470424B1 (en) * | 2016-06-08 | 2025-04-23 | Shanghai Jiao Tong University School of Medicine | Sequence of antibody heavy chain constant region for enhancing agonist antibody activity |
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| WO2024216089A1 (en) * | 2023-04-13 | 2024-10-17 | Bolt Biotherapeutics, Inc. | Anti-dectin-2 antibody combination therapy |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| IE913929A1 (en) | 1990-11-13 | 1992-05-20 | Immunex Corp | Bifunctional selectable fusion genes |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US7071171B1 (en) * | 1996-12-20 | 2006-07-04 | Board Of Regents The University Of Texas System | Unique dendritic cell-associated c-type lectins, dectin-1 and dectin-2 compositions and uses thereof |
| JP2003531149A (ja) | 2000-04-13 | 2003-10-21 | ザ・ロツクフエラー・ユニバーシテイ | 抗体由来の免疫応答の増強 |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| WO2006073921A2 (en) | 2004-12-30 | 2006-07-13 | The Rockefeller University | Compositions and methods for enhanced dendritic cell maturation and function |
| US20080286819A1 (en) | 2005-11-07 | 2008-11-20 | Ravetch Jeffrey V | Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof |
| NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| BR112016014952A2 (pt) | 2014-02-10 | 2017-09-19 | Merck Patent Gmbh | Inibição direcionada de tgfbeta |
| WO2015143091A1 (en) | 2014-03-19 | 2015-09-24 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
| AU2015349878A1 (en) | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| WO2017117269A1 (en) * | 2015-12-29 | 2017-07-06 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for dectin-2 stimulation and cancer immunotherapy |
| CN118108847A (zh) | 2016-08-07 | 2024-05-31 | 诺华股份有限公司 | mRNA介导的免疫方法 |
| US20190336615A1 (en) | 2017-01-27 | 2019-11-07 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| CN111032087A (zh) * | 2017-06-28 | 2020-04-17 | 小利兰·斯坦福大学托管委员会 | 用于dectin-2刺激和癌症免疫治疗的方法和组合物 |
| AU2020253621A1 (en) | 2019-04-05 | 2021-11-11 | Dren Bio Management, Inc. | Methods of depleting disease causing agents via antibody targeted phagocytosis |
| CA3198102A1 (en) | 2020-10-07 | 2022-04-14 | Dren Bio, Inc. | Anti-dectin-1 antibodies and methods of use thereof |
-
2021
- 2021-05-03 KR KR1020227041317A patent/KR20230005907A/ko not_active Withdrawn
- 2021-05-03 JP JP2022566470A patent/JP2023524092A/ja active Pending
- 2021-05-03 WO PCT/US2021/030466 patent/WO2021222894A1/en not_active Ceased
- 2021-05-03 BR BR112022020639A patent/BR112022020639A2/pt unknown
- 2021-05-03 CN CN202180031853.XA patent/CN115461122A/zh active Pending
- 2021-05-03 EP EP21727697.1A patent/EP4142881A1/en active Pending
- 2021-05-03 CR CR20220582A patent/CR20220582A/es unknown
- 2021-05-03 IL IL297782A patent/IL297782A/en unknown
- 2021-05-03 CA CA3175576A patent/CA3175576A1/en active Pending
- 2021-05-03 AU AU2021262828A patent/AU2021262828A1/en active Pending
- 2021-05-03 MX MX2022013616A patent/MX2022013616A/es unknown
-
2022
- 2022-02-03 US US17/592,323 patent/US11753474B2/en active Active
- 2022-10-28 CL CL2022003012A patent/CL2022003012A1/es unknown
-
2023
- 2023-07-21 US US18/356,928 patent/US12325750B2/en active Active
-
2025
- 2025-05-13 US US19/206,753 patent/US20250270329A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023524092A5 (https=) | ||
| AU2016226060B2 (en) | CD20 binding molecules and uses thereof | |
| JP2025000628A (ja) | ＮＫｐ４６結合タンパク質の可変領域 | |
| JP2021073224A (ja) | 結合分子 | |
| US20200377594A1 (en) | Humanized antibodies for cd3 | |
| JP2022515611A5 (https=) | ||
| JP2020510422A5 (https=) | ||
| CN110325209A (zh) | 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途 | |
| JP2020508334A5 (https=) | ||
| JP2017532037A5 (https=) | ||
| JP2020520665A5 (https=) | ||
| RU2019140602A (ru) | АНТИ-GARP-TGF-β-АНТИТЕЛА | |
| JP2019517539A (ja) | 併用療法 | |
| EP3892634A1 (en) | Anti-cd40 antibody, antigen binding fragment and pharmaceutical use thereof | |
| JP2022533538A5 (https=) | ||
| JP2023525695A5 (https=) | ||
| JP2024024114A5 (https=) | ||
| JP2021513961A (ja) | 変異型ｃｄ３結合ドメイン、及び疾患の治療のための併用療法におけるその使用 | |
| EP4154910A1 (en) | Binding protein having h2l2 and hcab structures | |
| CN120248131A (zh) | 靶向细胞因子和其使用方法 | |
| JP2024540148A5 (https=) | ||
| JP2021505637A (ja) | 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用 | |
| JP2023509373A5 (https=) | ||
| JP2024516645A5 (https=) | ||
| JP2018529672A5 (https=) |